Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 134

Results For "Chief"

2037 News Found

Affordable Sitagliptin combinations for diabetics to be sold at Janaushadhi Kendras
Healthcare | September 19, 2022

Affordable Sitagliptin combinations for diabetics to be sold at Janaushadhi Kendras

Sitagliptin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus


Parexel appoints Peyton Howell and Amy McKee
People | September 16, 2022

Parexel appoints Peyton Howell and Amy McKee

These moves are designed to strengthen the company’s medical and scientific focus and support its continued record growth through closer alignment of all aspects of strategy, sales, and delivery to delight customers


Ascletis Pharma completes patient enrollment in clinical for cure of HIV infection
Drug Approval | September 16, 2022

Ascletis Pharma completes patient enrollment in clinical for cure of HIV infection

The objective of this study is to evaluate the efficacy of ASC22 (Envafolimab) combined with Chidamide on the viral reservoirs of latently infected cells in HIV patients.


Cytel unlocks innovative clinical development expertise for APAC biopharma sector
Biotech | September 15, 2022

Cytel unlocks innovative clinical development expertise for APAC biopharma sector

Cytel has now established entities in Australia, Shanghai, Beijing, and Singapore, and plans to expand into Seoul and Tokyo in the coming years.


ProBioGen receives Employer of the Future and the Top Service awards
News | September 14, 2022

ProBioGen receives Employer of the Future and the Top Service awards

They also noted ProBioGen's digitalization investments and strategy, as well as its support for its employees.


Seagen, Astellas and Merck announce results of clinical trial investigating PADCEV with Keytruda  for urothelial cancer
Clinical Trials | September 13, 2022

Seagen, Astellas and Merck announce results of clinical trial investigating PADCEV with Keytruda for urothelial cancer

Results demonstrated a 64.5% confirmed objective response rate in patients treated with investigational combination of enfortumab vedotin and pembrolizumab


We will vaccinate 100% of the animals by 2025: Narendra Modi
Policy | September 13, 2022

We will vaccinate 100% of the animals by 2025: Narendra Modi

The Prime Minister addressed a major problem that is affecting the income of farmers which is the diseases of animals and emphasised that in this direction India is working towards universal vaccination of animals


Merck’s pembrolizumab plus chemotherapy showed sustained survival benefit versus chemotherapy alone
Clinical Trials | September 12, 2022

Merck’s pembrolizumab plus chemotherapy showed sustained survival benefit versus chemotherapy alone

In first-line metastatic NSCLC, KEYTRUDA-based regimens have now shown a five-year survival benefit in four trials


Lynparza with Bevacizumab demonstrates survival in certain patients with first-line advanced ovarian cancer
Clinical Trials | September 10, 2022

Lynparza with Bevacizumab demonstrates survival in certain patients with first-line advanced ovarian cancer

The Phase 3 SOLO-1 trial demonstrated 67% of advanced ovarian cancer patients with BRCA mutations receiving LYNPARZA were alive at seven years versus 47% of placebo patients